CBT Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH2553452D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

November 2018

Total pages

27

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

CBT Pharmaceuticals Inc (CBT) is a pharmaceutical company that develops innovative medicines for cancer indications. The company's pipeline products include CBT-101, cMet inhibitor is being developed to target the epithelial to mesenchymal transition pathway. Its CBT-101 is developed for various cancer indications, including kidney, esophageal, lung, gastric, colorectal and brain cancer. The company's other products in preclinical phase include, CBT-102, multi-targeted kinase inhibitor is being developed for liver, breast, colorectal and non-small cell lung cancer diseases. It operates in Taiwan and the US. CBT is headquartered in Pleasanton, California, the US.

CBT Pharmaceuticals Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

CBT Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

CBT Pharma Raises USD9.8 Million in Series A Financing 10

CBT Pharma Raises USD5 Million in Seed Financing 11

Partnerships 12

CBT Pharma Enters into Agreement with CrystalGenomics 12

Licensing Agreements 13

CBT Pharma Enters into Licensing Agreement with Crown Bioscience 13

CBT Pharma Enters into Licensing Agreement with Crown Bioscience 14

CBT Pharmaceuticals Inc-Key Competitors 15

CBT Pharmaceuticals Inc-Key Employees 16

CBT Pharmaceuticals Inc-Locations And Subsidiaries 17

Head Office 17

Recent Developments 18

Corporate Communications 18

Aug 16, 2018: CBT Pharmaceuticals announces new leadership structure to drive global expansion 18

Aug 28, 2017: CBT Pharmaceuticals Appoints Nationally Recognized Leaders in Oncology to Newly Established Scientific Advisory Board 19

Government and Public Interest 20

Oct 15, 2018: CBT Pharmaceuticals awarded NIH small business innovation research grant towards development of combination checkpoint inhibition 20

Clinical Trials 21

Apr 17, 2018: BT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of Its Multi-Tyrosine Kinase Inhibitor, CBT-102, at AACR Annual Meeting 2018 21

Oct 30, 2017: CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics 22

Sep 28, 2017: CBT Pharmaceuticals Announces First U.S. Patient Dosed in Phase 1 Clinical Trial of c-Met inhibitor, CBT-101, for Advanced Solid Tumors with c-Met Dysregulation 23

Apr 04, 2017: CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Highly Specific c-MET Inhibitor, Bozitinib (CBT-101), at AACR Annual Meeting 2017 24

Mar 30, 2017: First-in-Human Genolimzumab Phase 1 Study Initiated to Assess Safety and Preliminary Efficacy in Patients with Select Advanced Solid Tumors 25

Feb 23, 2017: CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Programmed Death-1 antibody, CBT-501, at ASCO-SITC Clinical Oncology Symposium 26

Appendix 27

Methodology 27

About GlobalData 27

Contact Us 27

Disclaimer 27


List of Figure

List of Figures

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List of Table

List of Tables

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

CBT Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

CBT Pharma Raises USD9.8 Million in Series A Financing 10

CBT Pharma Raises USD5 Million in Seed Financing 11

CBT Pharma Enters into Agreement with CrystalGenomics 12

CBT Pharma Enters into Licensing Agreement with Crown Bioscience 13

CBT Pharma Enters into Licensing Agreement with Crown Bioscience 14

CBT Pharmaceuticals Inc, Key Competitors 15

CBT Pharmaceuticals Inc, Key Employees 16

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022